alexa Prophylactic MTX Therapy to Prevent Choriocarcinoma | OMICS International
ISSN: 2157-7420
Journal of Health & Medical Informatics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Prophylactic MTX Therapy to Prevent Choriocarcinoma

Kazuo Maeda*

Department of Obstetrics and Gynecology (Honorary Professor), Tottori University Medical School, Yonago, Japan

*Corresponding Author:
Kazuo Maeda
Department of Obstetrics and Gynecology (Emeritus)
Tottori University Medical School, Yonago, Japan
3-125, Nadamachi, Yonago, Tottoriken, 6830835, Japan
Tel: 81-859-22-6856
Fax: 81-859-22-6856
E-mail: [email protected]

Received date: October 22, 2013; Accepted date: October 23, 2013; Published date: October 28, 2013

Citation: Maeda K (2014) Prophylactic MTX Therapy to Prevent Choriocarcinoma. J Health Med Informat 5:e113. doi: 10.4172/2157-7420.1000e113

Copyright: © 2014 Maeda K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Health & Medical Informatics

Choriocarcinoma is the very malignant tumor in gynecology characterized tumor metastases to whole organs and tissues, where the patientdied mainlydue to the brain metastasis. It developed after the evacuation of total hydatidi form mole, where no fetus was present, but the uterus was filled with cystic molar tissue, which was covered by abnormal trophoblasts, and its presence was confirmed by human chorionic gonadotraopine (HCG) in the blood and urine, and recently by ultrasonic image. A uterine choriocarcinoma is diagnosed by hemorrhage, enlarged uterus, ultrasound and the high HCG (usually beta HCG) in the blood and urine, and confirmed by histologic examination that the tumor was composed purely by trophoblasts but no molar villus pattern. In old times before 1960, the treatment was hysterectomy, which was followed by a pulmonary metastasis after one year and hematologically spread to whole body. The disease was frequent in East Asia old times. Maeda studied the trophoblastic diseases including choriocarcinoma , which was not a local malignancy but a systemic disease, and treated the metastases by Methotrexate (MTX), which was the most sensitive by choriocarcinoma, and achieved the disappearance of metastasis . Afterwards, the systemic MTX was administered before the hysterectomy (primary chemotherapy), where not only the metastasis but also primary uterine focus disappeared, if the drug was administered until the HCG disappeared in the blood and urine. The primary chemotherapy was effective to maintain the fertility of the patient; actually a case was normally pregnant after the primary chemotherapy. That was the first success of drug therapy of malignant neoplasia preserving fertility.

We intended to prevent the postmolar development of choriocarcinoma by prophylactic chemotherapy with MTX, after confirmation of the primary chemotherapy with MTX in 1960s at the Department of Obstetrics and Gynecology, Kyushu University, Fukuoka Japan [1].

The prophylactic chemotherapy was started as early as after the evacuation of total hydatidi form mole in 108 cases. The MTX was orally administered for 10mg a day for 7 days, 70 mg in total in typical cases. Two prolonged positive pregnancy test cases after molar evacuation were given 230 and 340 mg MTX in total until the urinary HCG was negative by the biological Friedman’s rabbit’s ovulation tests. The control were 81 cases composed of 42 cases of no chemotherapy and 39 cases received chemotherapy other than MTX.

No choriocarcinoma developed in 108 MTX treated cases, while 6 choriocarcinoma (7.4%) developed in 81 control cases. Significant difference (p=0.004) was noted between MTX and control groups in the development of choriocarcinoma.

The invasive mole was found in 2 (1.9%) in 108 MTX group and 2 (2.5%) in the control, where insignificant difference (p=0.77) was noted between two groups. It is natural, because molar tissue invaded the myometrium before the molar evacuation, and the outcome of invasive mole is benign after the hysterectomy.

Therefore, the prevention of malignant choriocarcinoma was successful by the MTX treatment in postmolar state. As the result, the development of choriocarcinoma is rare in Japan after the establishment of postmolar prophylactic chemotherapy. Another reasonwill be the early detection and removal of hydatidi form mole before trophoblastic invasion to the endometriumby the ultrasound imaging of early pregnancy in the first trimester.

Side effects of prophylactic MTX administration were shown, where no life threatening heavy toxicity was found (Table 1).

Toxic signs No. of the sign
Vomiting or nausea 29
Anorexia  16
Lip erosion     12
Stomatitis        34
Pharyngeal pain      27
Stomach pain 11
Diarrhea      5
Gingiva hemorrhage 5
Leukopenia<4,000  22
Headache       4
Skin rash          3
No toxicity in 23 cases  

Table 1: Systemic toxicity of MTX in the prophylactic chemotherapy.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12195
  • [From(publication date):
    April-2014 - Nov 13, 2018]
  • Breakdown by view type
  • HTML page views : 8402
  • PDF downloads : 3793
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]com

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version